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 1 
Abstract 
 Annually, approximately 375,000 people suffer from spinal cord injury (SCI) worldwide 
and many SCI patients develop secondary health conditions such as respiratory, cardiovascular, 
and urinary/bowel complications which negatively impact their daily lives. SCI occurs when there 
is damage to the spinal cord resulting in decreased motor functions,  decreased sensory functions, 
or paralysis. Days to weeks after initial impact, the lesion (area of injury) continues to increase in 
size in a process called progressive cavitation which demyelinates axons and inhibits effective 
axonal regeneration. In an in vitro model of progressive cavitation, Fitch et al. showed that 
activated macrophages cause cavities to form (areas devoid of cells) in astrocyte monolayers (Fitch 
et al. 1999). In this senior project, I developed an agent based model that replicates the process of 
cavitation as described in the in vitro experiment. My results showed that, similar to Fitch et al’s 
results, cavity size and astrocyte density increase with increasing cell speed. Due to the time, effort, 
ethics, and cost involved with in vivo studies, this model provides an alternative approach to 
predicting  optimal treatments leading to a more guided exploration of treatments that target and 
reduce progressive cavitation. 
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1  Introduction 
 
 Approximately 375,000 people suffer from spinal cord injury (SCI) worldwide and 12,000 
new SCIs occur in the United States annually (World Health Organization, 2013). Spinal                
cord injury (SCI) is characterized as damage to the spinal cord or nerves in the spinal canal (the 
cavity that contains the spinal cord). SCIs typically cause permanent damage to the body that 
results in a decline of body functions controlled by cells at and around the site of injury. Motor 
Vehicle Crashes account for 39.3% of SCIs, falls account for 31.8%, and violence (gunshot 
wounds), sports, and medical/surgical procedures combined account for less than 30% (National 
SCI Statistical Center, 2019). Up until World War II, serious SCIs usually resulted in death or a 
life with significant medical complications such as organ failure and blood clots. These 
complications also left most SCI patients confined to a wheelchair for the rest of their lives (Silver 
2005). However, research has advanced treatments available for SCI patients including 
immobilization of the spine on the scene of the accident, surgical procedures, stem cell transplants, 
and many drug therapies are currently in clinical trials giving health care providers and their 
patients hope for recovery. Current treatments focus on helping people with SCI continue to be 
independent and productive despite their injury (Zimmer et al. 2007; Mayo Clinic Staff 2017). To 
advance the possible treatments and minimize the negative effects of SCI, research into 
understanding the progression of injury and possible treatment targets are two of the biggest 
focuses of much of today’s research into SCIs. 
 
1.1  Spinal Cord  
 
An understanding of the spinal cord is key to the study of SCI. The spinal cord is a long 
and thin cylindrical shaped structure within the central nervous system (CNS) located within the 
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vertebrae in the spine (Squire et al. 2008; Guertin 2012). It runs from the base of the skull to the 
start of the lumbar spine (lower back) and consists of many neurons and glial cells. Neurons are 
tasked with transferring signals to muscle and other neurons in the Peripheral Nervous System 
(PNS) and CNS. Glial cells are nonneuronal cells in the CNS with subtypes such as astrocytes, 
oligodendrocytes, and microglia with roles such as protecting neurons, forming myelin (sheaths of 
proteins that wrap around the axons of neurons to improve signal conduction down the axon), and 
removing dead neurons from tissue respectively. Signal conduction is how neurons pass 
information, as electrical impulses, to and from the CNS to other neurons and cells outside the 
CNS (in the PNS).  Essentially, the spinal cord acts as a pathway to send sensory information from 
the body to the brain and motor information from the brain to the rest of the body. 
 
1.2 Spinal Cord Injury 
 
Spinal Cord Injury occurs when the above mentioned messenger pathway is disrupted 
resulting in motor and sensory deficiencies. Damage to the spinal cord occurs in two major steps: 
first the mechanical injury (also called the primary injury) then the chemical aftermath  (or 
secondary injury). The primary lesion is the structural damage that results from the mechanical 
injury causing a compression or laceration in the spinal cord (Ahuja, Cadotte, and Fehlings, 2018). 
This primary lesion, which occurs up to hours after injury, causes axons and the cell membranes 
of neurons to be damaged resulting in swelling of the spinal cord. The structural devastation 
incurred from the mechanical injury induces a cascade of biochemical events which cause 
functional damage often referred to as the secondary injury (Leal-Filho 2011). The secondary 
injury often lasts days to weeks after the primary injury occurs and is characterized by 
demyelination of axons, death of neurons, and activation of the immune system. Swelling of the 
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spinal cord results in low blood supply (ischemia) (Figure 1) and causes less oxygen and nutrients 
to reach cells (which causes neuronal death due to lack of nutrients) and development of a larger 
lesion referred to as the secondary lesion. In adults, whereas damage to the PNS is typically 
reversed by the body’s repair mechanisms, the CNS does not experience the same restorative 
behavior making SCIs more detrimental than other types of injuries in the nervous system 
(McDonald, Becker, and Huettner, 2004).  
Even though some cells die as a consequence of the mechanical (primary) injury, most of 
the cell death that occurs post SCI is a result of the secondary injury (Tator and Fehlings 1991). 
Death of oligodendrocytes elicits demyelination of axons because these glial cells can no longer 
produce the myelin sheaths necessary to keep axons myelinated. As part of the secondary injury, 
immune cells migrate to the injury site to clear away dead cells.  
Di Giovanni et al. suggested that the neuronal death, apoptosis, that occurs during the 
secondary injury may be due to up-regulation of the cell-cycle (Di Giovanni et al. 2003). They 
showed that in a rat model of spinal cord injury, neurons showing signs of apoptosis express cell-
cycle proteins suggesting these proteins are involved in neuronal damage and death. Since the cell 
cycle is usually down-regulated in non-mitotic cells, if cells enter the cell cycle, in this case it leads 
to apoptosis though the exact mechanism is not understood (Beattie et al. 2000). Another reason 
for neuronal death is damaged axons’ response to injury with neuronal degeneration (breaking 
down of damaged neurons) (Zheng et al. 2019).  
Astrocytes, star shaped glial cells, enlarge, become reactive, and proliferate to form a 
protective layer on the outside of the lesion. This layer of glial cells is typically referred to as the 
glial scar (Figure 1) (Cregg et al. 2014). The glial scar serves as a barrier between the injured tissue 
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and healthy tissue and limits the 
size of the lesion during the first 
few weeks of injury. However, 
since the glial scar is an additional 
layer of cells, it causes nearby 
axons which were not 
demyelinated due to the death of 
oligodendrocytes to become 
demyelinated due to limited space 
and in some cases, the 
demyelinated cells die. 
Additionally, inflammatory cells 
such as macrophages are 
recruited to the lesion core as a 
response to the cell death that 
occurs (Fujiki, Kobayashi, and 
Isono, 2003). These macrophages 
remove dead cells and within a 
few weeks post injury, a fluid filled 
cavity is left behind in the space 
that cells once occupied. Various 
studies including Fujiki et al. found that cavities form in the presence of activated macrophages as 
part of the secondary lesion, but the exact mechanism is not well understood (Figure 1) (Fujiki et 
Figure 1: Spinal Cord Injury Lesion. Various processes 
that occur post SCI. Cavitation occurs when cells die and are 
removed by immune cells leaving an area devoid of cells. The 
glial scar forms as a protective layer around the cavity   
(Mothe and Tator 2012). 
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al. 2005). This process is referred to as progressive cavitation because the scar is larger than its 
original size at the time of impact.  
 The cascade of events that occur during SCI includes severing of axons that are disrupted 
by the primary injury, demyelination of axons in both the primary (initial impact) and secondary 
injury (specifically the death of oligodendrocytes), apoptosis (cell death) and necrosis (tissue 
death) also occur in both steps of injury progression (Figure 1) (Leal-Filho 2011). Inflammation 
occurs in the secondary injury as the immune system responds to the injury, edema (swelling) 
occurs due to the inflammatory response, and excitotoxicity and oxidative damage to neurons 
occur due to increased release of glutamate (an excitatory neurotransmitter) resulting in 
overactivation of glutamate receptors on neurons which kills them. The primary injury may also 
rupture some blood vessels causing blood to leak out of them and cause hemorrhage (bleeding) 
which increases edema and causes vasospasm (spasms in arteries that lead to vessels constricting). 
Many of studies today focus either on neuroprotective measures to inhibit further damage that 
occurs in the spinal cord or on regenerative treatment to promote regeneration of myelin sheaths 
and severed axons and to improve survival of cells.  
 
1.3 Neuroprotective treatments  
 
 Neuroprotective treatments are important in reducing the negative impact of the secondary 
injury (Martin et al. 2015; Ahuja et al. 2016; Ahuja and Fehlings 2016). Different treatments have 
been investigated for properties that induce neuroprotection in the spinal cord. A few such 
therapies that target different aspects of the secondary injury are induced hypothermia (low body 
temperature), Geranylgeranylacetone (GCA), Granulocyte colony-stimulating factor (G-CSF), and 
Flavopiridol.  
 7 
Cooling of the body through induced hypothermia, in a controlled setting has shown to 
provide neuroprotection for cardiac arrest patients (Hypothermia after Cardiac Arrest Study Group 
2002). In a rat model of SCI, Lo et al. demonstrated the positive effect of inducing hypothermia to 
minimize neuronal damage (Kwon et al. 2008; Lo et al. 2009). Though this type of treatment is 
practiced in clinical settings for cardiac arrest patients and has been tested on SCI patients, it has 
not yet been approved for treating SCI patients (Levi et al. 2009). 
Geranylgeranylacetone (GCA) prevents increases of Tumor Necrosis Factor Alpha (TNF-
α) (a protein involved in inflammation) and neutrophils (white blood cells in the immune system) 
in the spinal cord after SCI (Fujiki et al. 2005). This limits secondary injury, neuronal death, and 
progressive cavitation in rat models of spinal cord injury. However, as with hypothermia therapy, 
even though this drug has undergone some clinical trials, it is not yet approved for use in patients 
with SCI (Ahuja and Fehlings 2016).  
 Granulocyte colony-stimulating factor (G-CSF) has shown to have neuroprotective effects 
in rat models of spinal cord injury by stimulating angiogenesis (development of new blood vessels) 
which results in recovery of motor function (Kawabe et al. 2011). These findings were used to run 
clinical trials to test the use of G-CSF in human subjects (Kamiya et al. 2015). Kamiya et al. found  
that this drug is safe and effective in human subjects but again it is not yet used in clinical settings.  
 Flavopiridol, derived from an Indian plant, is an inhibitor of cyclin dependent kinases, a 
group of proteins that regulate the cell cycle (Byrnes et al. 2007). Byrnes et al. investigated the 
benefits of administering Flavopiridol to rats after inducing a contusion SCI. They found that this 
drug reduces the volume of the lesion produced post SCI. This is significant because the larger the 
lesion size, the more overall damage to the tissue resulting in decline of body functions and 
increased axonal regeneration. Using the Basso, Beattie, and Bresnahan (BBB) locomotor scale 
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(typically used to test function recovery and movement post SCI), Byrnes et al. observed 
improvement in functional recovery of rats treated with Flavopiridol. Since motor function is 
typically impacted by SCIs, finding ways to reduce the damage as much as possible can help 
patients get closer to their normal functions before their SCI. They also concluded that astrocytes 
become less reactive upon treatment resulting in  reduced scarring around injury, an overall smaller 
lesion, and less negative impact on healthy tissue and cells. The last significant impact of 
Flavopiridol is reduction of cell cycle activation which resulted in less apoptosis. As Di Giovanni 
et al. found, inhibiting the activation of the cell cycle has neuroprotective benefits (Di Giovanni et 
al. 2005). 
 In a different model of glial scarring, Di Giovanni et al. studied the effects of Flavopiridol 
on rats after inducing a Traumatic brain injury (TBI). Similar to Brynes et al.’s study, these 
scientists found reduction of cell death, astrocyte proliferation, immune cell activation, lesion 
volume, and scar formation as well as increased functional recovery. These two studies support 
further exploration of flavopiridol as a treatment for CNS injury. However, though these studies 
are more than ten years old, this drug has only been used as a cancer drug (Tan and Swain 2002; 
Stephens et al. 2013; Orphan Drug Status for Alvocidib, 2014). 
 
1.4 Regenerative treatments  
 
 In addition to neuroprotection, neuroregeneration is key to repair the damage done by the 
secondary injury to help patients with SCIs recover some of the functionality they lost. There is 
no consensus on whether it is better to administer these drugs right after a SCI occurs or if it is 
better to wait until the secondary injury has stopped or slowed down (Martin et al. 2015; Ahuja et 
al. 2016; Ahuja and Fehlings 2016). A few therapies including  Chondroitinase ABC, stem cell 
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therapy, ibuprofen, and minocycline have been tested in animal models of SCI. Some have moved 
onto clinical trials but none of these are currently in clinical circulation. Chondroitinase ABC 
(ChABC), an enzyme derived from bacteria targets Chondroitin Sulphate Proteoglycans (CSPGs) 
which are proteins involved in glial scar formation and are critical in inhibiting axonal regeneration 
(Bradbury et al. 2002). Using an adult rat model of SCI, Bradbury et al. suggested the use 
of  ChABC to upregulate proteins involved with neuronal regeneration and promote axonal 
regeneration. Neural stem cells (cells capable of differentiating into a number of cell types) have 
been used to promote functional recovery and inhibit glial scar formation (Teng et al. 2002). 
Though Teng et al. showed that this inhibition is temporary, they suggested use of stem cells soon 
after SCI to reduce the reactivity of astrocytes that form the glial scar. Ibuprofen has shown in vivo 
(inside of a living organism) and in vitro (outside of a living organism typically in a test tube or 
cell culture on a dish) to limit inhibition of axonal growth that occurs in the secondary injury 
(Wang et al. 2009). Wang et al. used a rat model of SCI to show that ibuprofen can protect tissue 
in the spinal cord and stimulate axonal regeneration though the exact mechanism is not well 
understood.   
 Minocycline is a clinically prescribed drug that has been in circulation for over 30  years 
to treat diseases related to inflammation and more recently for neuroprotection (Garrido-Mesa et 
al. 2013). It has been used in models of traumatic brain injury, and various neurodegenerative 
diseases to reduce apoptosis. Festoff et al. and Wells et al., showed the benefits of Minocycline in 
rat and mouse models of SCI (Wells et al. 2003; Festoff et al. 2006). By inducing 
contusion/compression SCI in rat and mouse models, Festoff et al., and Wells et al., respectively 
found Minocycline improves functional recovery (better BBB scores). They also found the drug 
reduces the lesion/cavity size and apoptosis. Results from a phase II studies lacked significance 
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but the possibility of reducing the damage of the secondary injury warranted phase III trials to 
further investigate the benefits of using this drug in SCI patients (Casha et al. 2012). Though 
Minocycline is being used as an antibiotic to treat bacterial infections, there is no evidence that it 
is used to treat the secondary injury in SCI  (Goff et al. 2014). 
 
1.5 Research on cavitation 
 
Glial scar formation and progressive cavitation are two of the least well understood aspects 
of SCI. Faulkner et al. measured the effects of removing the glial scar by ablating (surgically 
removing) dividing reactive astrocytes and inducing SCI (Faulkner et al., 2004). They found 
inflammation increased, characterized by the presence of more inflammatory cells, when reactive 
astrocytes were removed. This led to a fivefold larger secondary lesion compared to the lesion in 
the control mice (with reactive astrocytes as is typical post CNS injury). This study shows that 
completely removing the glial scar increases progressive cavitation leading to a larger lesion size 
which negatively impacts healing in SCI patients. This finding supports previous claims that the 
glial scar has a protective function (Faulkner et al. 2004; Sofroniew 2009). 
 In a model of glial scarring and cavitation, Fitch et al., used a series of in vivo and in vitro 
experiments to show that inflammation post primary CNS injury leads to more tissue damage 
(including cavitation and glial scarring) (Fitch et al. 1999). The in vivo studies modeled the 
secondary injury that occurs during SCI to investigate the effects of chemical inflammatory 
processes separately from the primary injury that occurs due to the physical tissue and cell damage. 
By injecting rats with compounds involved in the activation of macrophages and microglia, Fitch 
et al., concluded that continuous inflammation led to progressive cavitation and glial scarring.   
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 Two in vitro models were then used to explore the effects of activated macrophages on 
neurons and astrocytes separately. Macrophages were isolated from adult rats and some were 
activated with Zymosan (a macrophage activator) while the control were not. Neurons were isolate 
from the lumbar and cervical spines of adult rats then plated in culture plates. Activated 
macrophages were then added for the experimental group and non-activated macrophages were 
used as controls. Fitch et al., found that activated macrophages and microglia decreased survival 
of neurons.  
 To investigate progressive cavitation, astrocytes were obtained and isolated from newborn 
rat cortices. These cultures were then seeded and left to settle for one to three days to form an 
astrocytic monolayer. Macrophages were used in two separate experiments as co-cultures with 
astrocytes or to make conditioned media (using three different macrophage concentrations). The 
macrophages and conditioned media were then added to astrocyte monolayers to replicate the 
chain of events that occur after CNS trauma. Fitch et al. calculated number of astrocytes, cell 
density, and size of cavities and found that activated macrophages both in co-culture or conditioned 
media caused progressive cavitation in the astrocyte monolayer. Although their model resulted in 
multiple smaller cavities, since the in vitro model uses cells without a physical injury, the process 
of cavitation in vitro leads to many cavities whereas in vivo there is typically one large cavity 
(Figure 1). They found increased astrocyte density, and suggested astrocyte migration as a possible 
mechanism for cavitation. Fitch et al. also demonstrated that using an anti-inflammatory agonist 
blocks activation of inflammation and reduces cavity formation. The in vitro model using 
conditioned media is the main basis for my in silico (on a computer) model and simulations. 
 Even though many studies have been done to help us understand SCIs better and find new 
treatment possibilities, patients with SCIs do not have many treatment options (Martin et al. 2015). 
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Other than surgery, physical therapy, and the few treatments out there, some patients may be 
eligible for clinical trials but most of the treatments available focus on preventing additional 
mechanical damage rather than stopping the process of the secondary injury as soon as possible. 
 
1.6 Computational models 
 
 Computers have made study of complicated systems faster and more efficient allowing us 
to create computational models using computer science, math, and physics (Brodland 2015). These 
models are becoming an important complement to other types of studies, helping us visualize 
systems, understand how they work, and predict theirs behaviors and responses to changes in the 
environment. One of the most important aspects of a computer simulation is that it uses a pertinent 
model that reflects the system. The aspects included to make a model appropriate, that is including 
or excluding certain aspects of the system, depend heavily on the questions being asked. Once the 
question being asked is well defined, the type of model can be chosen and from there, the necessary 
parameters can be identified. Studies that use models for simulation have various applications such 
as evaluating performance, assessing and managing risks, and evaluating possible actions to be 
taken. Computational models have become especially useful in computational biology, for 
example, in the study of proteins, the immune system, and cancer (Krogh et al. 1993; Norton et al. 
2010; Germain et al. 2011). To choose an appropriate model we must first examine the different 
kinds of computational models and their applications. 
 One of the ways in which computational and mathematical models are classified is discrete 
versus continuous models. A discrete model has variables (called state variables) that change at 
specific points in time when an event or change in state occurs (Birta and Arbez 2007). In 
simulations of these types of models, time changes in leaps (is not continuous). A continuous 
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model on the other hand, is one in which time is continual and variables change constantly based 
on the varying state of the system (Banks 1998). This type of model is used for example to measure 
concentration of cells or objects in an environment over time. However, when this type of model 
is simulated computationally, we do not have data points for every moment in time from the actual 
system so it is not actually completely continuous but the variables usually fall within a range of 
values. The more data points the model has, the more accurate it is because there are less gaps. 
There are also hybrid models which have elements from both discrete and continuous models 
(Martin and Raffo 2000; Bortolussi and Policriti 2008). These models use ideas from continuous 
modeling for dynamic variables/aspects of the model and ideas from discrete modeling for 
variables that change based on a specific timeline. These models can be described as discrete 
variables (that jump) in a continuous environment (that flows).  
 Discrete models typically come in two types: lattice and off-lattice. A Cellular Automaton 
(CA) is an example of an on lattice grid of cells (Wolfram 1984; Adamatzky 1994). Cellular 
automata have three major components: an array of cells, a neighborhood, and rules for 
interactions/transitions. Each cell in a CA can have a finite number of states that change based on 
the rules of transition at specific points in time depending on events that occur in its neighborhood. 
On the other hand, in off lattice (on a continuum of space) agent based models (ABMs), the system 
is typically one or a few autonomous agents that act and interact in a given environment (Bonabeau 
2002). Each agent makes its own decisions which can impact and be impacted by the actions of 
other agents. This type of model allows for simulation of complex behaviors of systems that are 
not well understood because unlike most discrete models, it is not based on any equations (An et 
al. 2017).  Since many biological systems have not yet been explained by equations, using ABMs 
allows one to give the model as much or as little information as is known about the system  
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  It is important to investigate the pros and cons of simulations in silico. One of the biggest 
cons of simulation is accuracy (Banks 1998; Birta and Arbez 2007). Since knowledge of the 
processes that occur during SCI is limited, one may argue that this may result in an inaccurate 
model and simulation. To resolve this issue, we add in as much detail from the real world and try 
to fit our model to an in vivo or in vitro study by duplicating their results using our in silico model. 
The pros of simulation are vast. Whereas lab equipment to maintain model organisms, induce SCI, 
monitor changes on a cellular level, and other steps in the in vivo and in vitro process tend to be 
expensive, the price of computer simulation is close to nothing. Additionally, simulations are less 
invasive making experimentation with them more ethical and low stakes since it does not involve 
any living things. When simulations produce unexpected results, they force researchers to consider 
underlying reasons for the cause of these results (Brodland 2015). Simulations can also require 
less effort, technical limitations, and are less time consuming than working in a wet lab (Zhou and 
Kuhl 2011). Even though some simulations may require high amounts of processing power and 
may take hours to days to run, unlike in vivo and in vitro experiments, the experimenter can define 
simulation time. Having the power to define simulation time can allow researchers to run an 
experiment that takes days to run (in vivo  or in vitro) in just a couple hours in silico.  
 
1.7 Spinal Cord Injury Models 
 
 Within the last decade alone, there have been a multitude of in silico models of the spinal 
cord and spinal cord injury developed by scientists to increase our understanding of these two 
systems and investigate some of their processes. In an agent based model of pressure ulcers (tissue 
damage due to continued pressure), Ziraldo et al. used a model of tissue cells to simulate formation 
of pressure ulcers (PU) and test possible treatment options for reducing PU (Ziraldo et al. 2015). 
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They found that anti-inflammatory treatments could reduce the level of expansion of inflammation 
and tissue damage. They suggested use of ABMs to increase understanding of mechanisms 
involved with PU and investigate therapies to improve patient outcomes. Solovyev et al. developed 
a hybrid model to combine hyperemia (blood build up in vessels) and PU (Solovyev et al. 2013). 
Incorporating an Ordinary Differential Equation (ODE) model (which uses a set of ODEs) for 
hyperemia and an ABM for PU, they showed that individuals with SCI are more likely than those 
without SCI to develop ulcers as a response to pressure on their spine.  
 Finite element models (FEMs) are another type of model which has a set (finite) number 
of components (elements) that interact with one another at their points of connection 
(Zafarparandeh et al. 2014). Yuk created a finite element model of spinal cord tissue for use in 
understanding the mechanical injury of SCI (Yuk 2016). Another finite model of the spinal cord 
was developed by Zafarparandeh et al. to improve understanding of its biomechanics (structure 
and mechanism of movement) (Zafarparandeh et al. 2014). Maikos et al. developed a 3D FEM to 
simulate spinal cord injury in rat models (Maikos et al. 2008). Their model serves as yet another 
way to study the biomechanics of SCI especially in research involving model organisms. Though 
there are models of the spinal cord as well as spinal cord injury, there is little evidence of 
development of in silico models of progressive cavitation.  
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2 Methods 
 
 Since this in silico model aimed to replicate Fitch et al.’s in vitro study, with astrocytes 
interacting with one another and reacting to changes within their environment (treatment with 
active or nonactive macrophage conditioned media), an agent based model was used.  
2.1 Outline of Approach 
 
To accomplish the goal of creating a model that exemplifies astrocytes and consequences of 
SCI, the process of making a simulation as defined by Robert Shannon was used (Shannon 1998). 
The bullet points represent how each of Shannon’s steps was applied to this in silico model.  
1. Define problem. What questions is this project trying to answer?  
 The goal of this project was to investigate (in silico) progressive cavitation which 
occurs during SCI. To do this, the in vitro results of Fitch et al. needed to be replicated 
then used to consider different treatment targets as possible ways to decrease 
cavitation during SCI (Fitch et al. 1999). 
2. Plan project to ensure the necessary computational resources are available.  
 An agent based model of astrocytes was developed using Processing (version 3.3.6) 
which makes visualizing the cells simple.  
3. Define the system. To create a model, the system being modeled must be clearly defined. 
A system is composed of a group of interacting factors that all work towards the same goal 
and are related to one another. This step includes understanding how the system works and 
deciding which parts to include and which to leave out.  
 To start off with a simpler scenario, the system did not include a macrophage 
coculture. This system is an in vitro cell culture of astrocytes whose movement is 
either affected by active or nonactive macrophage conditioned media (to replicate the 
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processes that occur during SCI). The astrocytes also experienced a drag force that 
represents their movement within the extracellular matrix or media and they 
interacted with each other through a spring force so as to limit the possibility that 
they completely cross one another.  
4. Formulate an idea of what the model will look like. A model is a depiction or replication 
of a real world system which can then be used to predict something about the system.  
 This model included astrocytes depicted as blue ellipses placed in the middle of a 
500x500 pixel screen where one pixel corresponds to one micron. It also had either 
activated or nonactivated macrophage conditioned media which was controlled by a 
variable that impacts astrocyte movement within the astrocytic monolayer and was 
either true for active or false for nonactivate (macrophage conditioned media). 
5. Preliminary design of the experiment. This is where the factors being altered are 
determined and necessary data to support creation of the model is obtained. This step 
involves determining the plan for the experiment and deciding on measures of 
effectiveness. 
 In addition to the in vitro experiments from Fitch et al., parameters such as cell size 
and speed were necessary to replicate normal conditions of cells. Measure of 
effectiveness was whether or not increasing the speed of astrocytes in the activated 
macrophage media experiment also increased the astrocyte cavity area similar to 
Fitch et. al.’s in vitro cavitation assay.  
6. Preparing input data. Finding and documenting data listed in step 5 for the model.  
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 Details of parameters such as the average size of astrocytes, their movement speed, 
their interactions with one another, and how they are typically plated in vitro was 
gathered (see Table 1).  
 
Table 1: List of parameter values. Range values for the three main variables in the model. 
Parameter Value 
Astrocyte Size 20 – 25 microns (Bear et al. 2007) 
Cell culture density 80% confluency, cells fill up 80% of the plate/well 
(Arora et al. 2008) 
Astrocytic Speed Not active: 
100 microns/24 hours (Emmett et al. 1991) 
Active or around active cells: 
220 microns/24 hours (Zhou et al. 1990) 
481 microns/48 hours (Kuiper et al. 2009) 
10 – 70 microns/hour (Környei et al. 2000) 
 
7. Translating model to a simulation. A simulation is an emulation of real world systems 
over time using a model with data gathered from observing the system (Banks 1998). It 
shows the actions of the system and allows for experimentation to make inferences about 
future actions and characteristics of the system.  
 After gathering input data, the simulation was given rules for interaction (such as 
bouncing off of other cells in the case of a collision) and run for a total of 72 hours. 
Values from the literature (see table 1) were used to obtain a baseline for the astrocyte 
speed both in the nonactive state and when active macrophage conditioned media was 
added. Using the average active speed, simulation time was calculated as follows:  
  (480 microns/48 hours)= 10 microns/1 hour 
  (10 microns/1 hour ) * (1 iteration/0.2 microns) = 50 iterations/hour 
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For the first 2 days (48 hours) the cells moved at 0.084 microns as they settled. 
At the 48 hour mark, if the cells were activated in the simulation (the equivalent of 
being treated with activated macrophage conditioned media), the speed changed to 
0.2 which corresponds to 10 microns/hour. Cavity size (white space in the model) 
was calculated at the end of the settling period and again at the end of the simulation 
(hours 48 and 72) (See 2.3 Image Processing). Hour 48 of simulation corresponds to 
the start of the treatment with either activated or nonactivated macrophage 
conditioned media (also called the 0 point of treatment or 0 hours into day 3). Hour 
72 corresponds to the end of the simulation which is also 24 hours since treatment. 
The cavity size of the control (nonactivated macrophage conditioned media) at 24 
hours is normalized to 1.  
8. Validating the model. Affirm the validity of the model based on the real system’s results 
and analyze the expected operation and trends in the models as compared to the system.   
 Preliminary results were compared to those of the in vitro experiments described by 
Fitch et al. (Fitch et al. 1999). Observations showed that the activated condition does 
not correspond to the value in Fitch et al.’s experiment so other values within the 
range (10-70 microns/hour) described by Környei et al. were used  (Környei, et al. 
2000). Based on the preliminary data with sampling of different speeds, there were 
speed values that resulted in cavity sizes that correspond to the cavity sizes explained 
by Fitch et. al.  
9. Final design of the experiment. Planning any changes to original experiment and 
considering which statistical tests will be used.  
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 Though the model was validated, the preliminary results only included one trial per 
speed. More trials were needed to obtain a larger more representative sample size. 
Once the data was collected, t-tests were important to show the active treatment is 
statistically different than the treatment with nonactive macrophage conditioned 
media. 
10. Experiment. This involves deciding on sample size, and running the simulation to gather 
data. 
 Thirty separate simulations were run to increase sample size for each value and gather 
the data from the start (48 hours) and end (72 hours) of the treatment period (day 
three at 0 hours and 24 hours) and images of the cells were saved at 6 hour intervals 
beginning at time 0 of treatment (48 hours from plating).   
 Additional experimentation using different values for the spring constant that affects 
the way cells bounce off one another was done to show preliminarily the effects that 
changing this variable has on cavity area.  
11. Analysis and Interpretation of the data gathered. Deciding which statistical tests make 
the most sense based on the data. Interpreting what the results mean and the implications 
they have.  
 Used image processing data to analyze differences in white space between the start 
and end of day 3 for each of the thirty simulations to determine delta (change) in 
cavity size. Ran statistics on the change in cavity size data (see section 2.4 statistics) 
to confirm validity of data collected and made conclusions based on  the results. 
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12. Documenting results and implementing them.  
 This senior project is a documentation of the in silico model’s results. Simulation 
with a range of values for parameters such as speed, spring constant for bounce, or 
adding macrophages as a co-culture can be used to show possible treatment targets 
to decrease cavitation post SCI. This data can eventually be used for in vitro studies 
though that is out of scope for this project. 
 
2.2 Explanation of simulation 
  
 Due to the progression of the lesion during SCI and the autonomous nature of astrocytes in 
the spinal cord (they act upon and interact with their environment and one another), an agent based 
model of spinal cord injury was developed to simulate progressive cavitation in SCI. The model 
used for this simulation is based on Fitch et al.’s in vitro model of progressive cavitation. In this 
in silico model, a screen that is 500x500 pixels was used to correspond to a 500x500 micron well, 
with 1 pixel = 1 micron. Astrocytes, ellipses 20 microns in diameter, were placed on the screen in 
80% confluency to simulate plating of cells and allowed to settle for 48 hours (2 days) (Környei, 
et al. 2000). After 2 days, the cells either changed their speed (by changing stepSize) if they were 
treated with the activated macrophage conditioned media or stay the same if they were treated with 
nonactivated macrophage conditioned media. Cells were then allowed to move around randomly 
for another 24 hours. The data was analyzed at hour 0 of day three (after cells have settled) and 
then again when the simulation ended at the 24 hour mark of day 3. 
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Table 2: Classes in simulation. All the classes, their attributes and methods.  
Class (objects) Attributes  Methods (What the objects can do) 
Cell (parent class) 
 
 
Float size:  size of the cell 
Pvector location: the location of the cell  
Pvector velocity: the cell’s speed 
Pvector acceleration: how quickly the 
cell’s speed increase 
display(): displays cell  
update(): updates the location of the 
cell based on the acceleration and 
velocity 
 
applyForce(): applies a force by 
adding it to the acceleration 
Astrocyte 
(extends Cell) 
float stepSize: number of microns 
astrocytes move per iteration 
 
display(): displays the cell as a blue 
ellipse 
 
randStep(): moves the cell by 
randomly selecting a value: -1, 0, or 
1 then multiplying it by setpSize and 
adding the total value to the location 
 
checkEdges(): constrains the cells to 
the screen’s limits so they cannot go 
off the screen 
                
bounce(): given another cell and a 
spring force, allows cells to spring 
slightly when they come in contact so 
they do not overlap uses Hooke’s law 
Force = -kx, k = spring constant and 
x = difference between desired 
distance and actual different between 
cells 
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Table 3: Main Method. All the functions and parameters for the main sketch.  
 
Parameters Functions 
Main  Astrocyte[] astrocytes: array of 
500 astrocytes  
                 
int state: a simulation is either in 
the 0 state oplating or the 1 state 
where cells are moving around 
 
int cellSize:  size of astrocytes – 20 
microns 
 
int iter: keeps track of how many 
draws have occurred to track 
simulation time 
                
int simNum: simulation number to 
allow multiple simulations to be 
with the same conditions 
(active/nonactive treatment and 
step size combination) 
 
boolean active: whether the media 
is conditioned with activated (ture) 
or nonactivated (false) 
macrophages  
                
int hour: hour within the 
simulation 
 
float activeStep: step size (speed) 
for activated cells 
 
float springConstant: the (k) spring 
constant of the cells 
 
int trialNum:  trial number to help 
separate trials (with different 
activeSpeed) into different folders 
setup(): sets all the original  values of the 
attributes, the background color, display size, sets 
file to “NonActivated,” and creates the output file. 
 
draw(): run simulations starting with the non-
activated condition. 
• Place cells on screen in a grid like space 
with a randomness of +/- 2 pixels  
• Change state to 1 so they start moving. 
Allow cells to bounce off each other to limit 
overlap 
• If cells have settles for 48 hours (iter = 
2400), analyze image and start saving 
images every six hours. If the cells are in 
active conditioned media, change the 
stepSize of the cells. 
• Once the simulation reaches 24 hours 
(3600 iterations), analyze the image then 
switch to the “Activated” simulation and 
repeat the process. If both activated and 
non-activated simulations have run for a 
given simulation number (simNum), go to 
the next simulation. 
• Stop simulations once simNum is greater 
than 30 
• Close the output file so it can be viewed by 
the user. 
 
analyzeImage(): analyze the screen to determine 
how many white pixels there are 
 
bounceCells(Astrocyte[]astrocytes):  check each 
cell against all other cells in an array excluding 
itself to determine which ones are overlapping. If 
any cells are overlapping, the force from bounce() 
is applied to one cell and the negative of the force 
is applied to the other cell. Once all cells are cross 
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and text files (for bookkeeping and 
ease of analysis) 
                    
FOR ANALYSIS  
PrintWriter output: output file 
                
int whitePixel: number of white 
pixels on the screen 
 
String filetype:  output file name 
 
String filename: activated or non-
activated 
checked against one another, a drag force (that 
mimics movement of cells on a petri-dish) is 
applied to each cell and its location is updated 
based on all the forces on it.  
 
 The simulation of progressive cavitation post SCI using the in silico astrocyte model runs 
30 simulations for each treatment type (active/nonactive macrophage conditioned media). Each 
simulation starts off at the initial state where the cells are placed on the screen in confluency similar 
to cells being plated (leftmost image of Figure 2). After settling for 48 hours (middle images in 
Figure 2), the image is analyzed. The astrocytes’ stepSize changes if the treatment is active 
macrophage conditioned media or stays the same if the treatment is nonactive macrophage 
conditioned media. The cells are allowed to move for another 24 hours and the final image is 
analyzed (rightmost images in Figure 2).  
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Figure 2: Schematic for methods. The leftmost image is a representation of when the cells are 
placed on the screen. The middle image shows the cells after settling (at 48 hours)  and the 
rightmost image shows cells 24 hours after treatment (72 hours since plating).  
 
 
2.3 Image Processing 
 
 Images are analyzed using the function analyzeImage() in the main sketch. Pixels are 
loaded and whitePixels, a variable that counts the amount of empty space, is set to zero. The white 
pixels represent the background and cavitation (since at plating, as seen in Figure 2, there are some 
white pixels in the background). Two for loops are used to go through every column and every 
row of pixels. If the pixel is white, it is turned into a purple pixel (for visual ease of catching 
incorrectly colored pixels) and the variable whitePixels increases by one. The pixels are then 
updated using the updatePixels() function to show the purple pixels (see Figure 3).  
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 The accuracy of analyzeImage() function was tested using all the images shown in Figure 
3. A, B, C, and G all show the original images that test the accuracy of analyzeImage() in 
differentiating between white pixels and non-white pixels. These images were also tested using 
the same blue/green color of the astrocytes in the simulation instead of the black and yielded the 
same results. Images D, E, F, and H show the white pixels changed to purple pixels. Table 4 is a 
quantified version of image 3. It shows that A, B, and G all had the correct number of white pixels 
accounted for while C had 316 white pixels not accounted for the reason for this discrepancy is 
unknown. However, compared to the overall number of pixels, 316/250000 = 0.002528. Less than 
1% of the pixel values are incorrect.  
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Figure 3. Images used to test analyzeImage(). A, B, C, and G show original images that are 
used to test the image analysis function. A, B, and G are half white half black while C is a quarter 
black and three quarters white. Images D, E, F and H are the recolored version of A, B, C, and 
G. Each purple pixel was once a white pixel which the analyzeImage() function converted to a 
purple one. 
 
   
 
A B C 
G 
D E F 
H 
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Table 4: Image processing test results. The number of white pixels in A, B, and G were correctly 
calculated white 316 white pixels were missed in the calculation for image C.  
Image letter (see 
Figure 3) 
White pixels calculated by 
analyzeImage() function 
Total pixels 
in image 
Actual number 
of white pixels 
Percent 
error (%) 
A (half white) 125000 250000 125000 0 
B (quarter white) 187500 250000 187500 0 
C (half white) 124684 250000 125000 0.2528 
G (half white) 125000 250000 125000 0 
 
 The text file produced for each set of 60 simulations (30 for control and 30 for 
experimental) was created using image processing of each pixel on the display screen. Based on 
the 50 iterations/hour calculation for simulation time, when a simulation has reached 2400 
iterations, that corresponds to 48 hours or start of treatment and the image is analyzed. For the 
astrocytes, column of pixels is 0-499 and row of pixels is 50-449 to analyze the space where the 
cells are placed (plated in the middle of the screen; Figure 4). The cells are analyzed again at 72 
hours (end of simulation). Cavity area is calculated as (white pixels at time x in active 
treatment)/(white pixels at time x in nonactive treatment) to give a value for how many folds larger 
the cavity treated with activated macrophage conditioned media is (x is either 48 or 72 for start 
and end respectively).  
 Once the raw data was collected, it was analyzed in excel to obtain the average white space 
for activated and nonactivated treatments. The average increase in area with control normalized to 
1 was calculated for each “active” treatment.  
 
 Average increase in area = 
average white pixels in “active” at end of treatment) 
average white pixles in “nonactive” at end of treatment) 
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Since white space in the nonactive state is the background and white space in the active state is 
background + cavity, cavity formation was calculated based on the change in whitespace from the 
start to end of each treatment. (Cavity formation = white pixels at end – white pixels at start). 
 
        
Figure 4. Example of astrocytes image analysis. The leftmost image is the astrocyte monolayer 
at 48 hours, directly before the activated macrophage conditioned media is added. The middle 
image is at 72 hours, 24 hours after activation. The rightmost image shows all the white pixels 
turned purple. The black box represents the area where the white pixels were evaluated.  
 
 
2.4 Statistics 
 Statistical analysis was done using R comparing between different aspects of the control 
astrocyte cultures with nonactive macrophage condition media and the experimental astrocyte 
cultures with active macrophage conditioned media.  
The hypotheses for the data are:  
 
 Null hypothesis 1 (Ho1): There is no difference between the white space at the start points 
(hour 48) for activated and nonactivated macrophage conditioned media treatments. 
 Alternative hypothesis 1 (HA1): There is a difference between the white space at the start 
points (hour 48) for activated and nonactivated macrophage conditioned media treatments. 
 Ho2: There is no difference in cavity area at end point (72 hours) between “active” and 
“nonactive” treatments.    
 HA2: There is a difference in cavity area at end point (72 hours) between “active” and 
“nonactive” treatments.    
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 Ho3: There is no difference between each “active” treatment condition in Fitch et al.’s in 
vitro model and its corresponding “active” treatment condition in silico. 
 HA3: There is a difference between each “active” treatment condition in Fitch et al.’s in 
vitro model and its corresponding “active” treatment condition in silico. 
 
 To test the first set of hypotheses, t-tests with equal variance were run for each of the critical 
values 1.6, 1.8, and 2.4 (these correspond with Fitch et al.’s results) for increase in cavity size. 
Since the purpose of this experiment is to show that the cavity size increases when there is a spinal 
cord injury (represented by activated macrophage conditioned media), for the second set of 
hypothesis, the t-tests with equal variance were run on the change in cavity size from hour 0 of 
day three to hour 24 of day three. To account for multiplicity of p-values (running three t-tests), 
the Bonferroni correction was applied to the critical p-value ( = 0.05): 0.05/ 3 = 0.0167 =  (new 
critical p-value). The model’s assumptions were conducted using R version 1.1.463 (See 
Appendix). Fitch et al. only included the summary of their data. Therefore, to check if increase in 
cavity size for different levels of activation in vitro corresponds with the increase in cavity size of 
the in silico model, a z-test was used with their data treated as the population. Average of the 
population from the in vitro model versus the data from the in silico model was used to test the 
third set of hypotheses. 
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3 Results 
 
 I developed an agent based model of progressive cavitation and used it to show that cavity 
area increases as astrocyte speed increases. A series of 30 simulations for each “active” treatment  
(activated macrophage conditioned media) was used to establish similarity between the outcomes 
of my in silico model and Fitch et al’s in vitro model. The control “nonactive” treatment did not 
cause cavities to form in the astrocyte monolayer. These simulations showed that at 24 hours post 
“active” treatment, cavities formed (Figure 5). The white space (background) in the control is 
significantly different than the white space (background + cavities) in the “active” treatments. The 
agent based model of cavitation closely replicates the findings of Fitch et al.’s in vitro cavitation 
model. Additionally, though I did not intend to include astrocyte density as a factor in my 
simulation, the model showed areas where astrocytes are more closely packed together and these 
increased as astrocyte speed increased.  
 Qualitatively, my in silico model of progressive cavitation (Figure 5B) compares to Fitch 
et al’s in vitro model of progressive cavitation (Figure 5A). Figure 5A shows the nuclei of the 
astrocytes which are closely packed meaning the astrocytes are closely packed. The formation of 
cavities (identified with asterisks) causes astrocytes to move close together resulting in an 
increased astrocyte density in some areas (shown by arrows) and no astrocytes in other areas 
(cavities) within the astrocyte monolayer. Figure 5B is a snapshot of my in silico model at the end 
of a simulation showing an example of entire astrocytes which received the “active” treatment. 
Similar to the in vitro model, these astrocytes form cavities which also causes the astrocytes to be 
closely packed. Although the astrocyte densities in my in silico model were not quantified, Figure 
5B shows there are areas where astrocytes are more closely packed together. Though at first glance 
Fitch et al.’s cavities seem to be larger than the cavities formed by my model it is important to take 
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into account the scale differences between the two images as well as the distinction between 
imaging the cell nuclei versus the entire cell.   
 
                 
 
Figure 5: In vitro vs. in silico cavitation model comparison. A. shows cavities formed in vitro 
from Fitch et al.’s study. The white dots are the astrocytes’ nuclei (Fitch et al. 1999). Scale bar, 
250 μm. B. shows the cavities formed from my simulation. The white circles are the astrocytes 
(the entire cell). Scale bar, 50 μm. The arrows in both models show areas with increased astrocyte 
density and the asterisks show cavities formed due to the active macrophages conditioned media.  
 
  
 The values used to test the effect of different speeds on astrocyte cavity area are presented 
in Figure 6. As speed of astrocytes with the active treatment increased, so did the cavity area. The 
cavity area consistently increases but once speed is large (around the 0.8 – 0.9 microns/iteration 
range which is about 40 - 45 microns/hour) the area starts to plateau. Since the cells have a limited 
area (500x500 display screen) and their overlap is limited, it is expected that at some point 
increasing the speed will not cause an increase in cavity area. 
250 μm 
50 μm 
A B 
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Figure 6: Effects of astrocyte speed on increase in cavity area. As the speed of astrocytes in 
the activation treatment increases, cavity increases. The cavity formation starts to plateau at 0.8 
microns/iteration). 
 Quantitatively, my in silico model of progressive cavitation (Figure 7B) compares to Fitch 
et al’s in vitro model of progressive cavitation (Figure 7A). Each of the “active” treatment levels 
is significantly different than the control “nonactive” treatment. Based on the Bonferroni 
correction, the critical p-value, , is 0.0167. For all three cavity sizes, we reject the null hypothesis 
(Ho2) therefore we accept the alternative hypothesis (HA2). Increase in cavity size is explained by 
activation of macrophages for 1.6, 1.8, and 2.4 fold increases in cavitation. 1.6 (t[58] = -95.321; P 
< 0.0001), 1.8 (t[58] = -140.97; P < 0.0001), and 2.4 (t[58] = -139.19; P < 0.0001). Additionally, 
for the comparison of white pixels at the start point, we fail to reject the null hypothesis (Ho1). 
There is no difference between the white space at the start point (0 hours into treatment) for 
activated and the white space at the start point for nonactivated macrophage conditioned media 
treatments for all “active” treatment levels. 0.25 microns/iteration (t[58] = 0.37388; P = 0.7099), 
0.3 microns/iteration (t[58] = -1.2877; P = 0.203), and 1.4 microns/iteration (t[58] = -0.91903; P 
= 0.3619). 
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 With each cell density used for the conditioned media in vitro there is a corresponding 
speed that gives a similar cavity area in silico. 5 *106 macrophages/ mL corresponds to a speed of  
0.25 microns/iteration and a 1.6 fold increase in area, 10 *106 macrophages/ mL corresponds to a 
speed of  0.3 microns/iteration and a 1.8 fold increase in area, and 12 *106 macrophages/ mL 
corresponds to a speed of 1.4 microns/iteration and a 2.4 fold increase in area (Appendix - 
Supplementary Figure S1). Based on the average of the population from the in vitro experiment, 
z-test showed no significant difference between each pair of corresponding values in vitro and in 
silico. 0.25 microns/iteration (μ = 1.6,  = 0.2 ), z(N=2)= 0.05010038, p = 0.96; 0.3 
microns/iteration (μ = 1.8,  = 0.15), z(N=2)= -0.0962963, p = 0.92;  1.4 microns/iteration (μ = 
2.4,  = 0.3), z(N=2)= 0.08463757, p = 0.92. Preliminary results of changing the spring constant 
for cells showed that as spring constant increases, the astrocyte cavity area decreases (Figure 8). 
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Figure 7: In vitro vs. in silico increase of cavity area. The in silico model (B) closely matches 
the in vitro model (A) described by Fitch et al., providing a measure of success. A. In vitro 
model from Fitch et al.’s experiment. The values next to each activated condition is on the scale 
of 106 macrophages/mL. Increasing density results in an increase in cavity area. B. In silico 
model with different levels of “active” treatment. Increasing speed of astrocytes results in an 
increase in cavity area. In panels A and B, all the “active” treatments are significantly different 
than the control. (* p<0,05; ** p<0.01; *** p<0.001) 
A 
B 
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Figure 8: Effects of spring constant on change in cavity area. As the spring constant 
increases, cavity size decreases. 
 
 
 
4 Discussion  
 
 
 My model and simulation demonstrated the successful use of an in silico model to replicate 
the studies of an in vitro model of progressive cavitation. This novel agent based model used 
parameters based on in vivo and in vitro experiments (Table 1) and showed the increasing cavity 
area was not significantly different to Fitch et al.’s in vitro model. The different “active” treatments 
in the in silico model are statistically different than the control “nonactive” treatment (Figures 5 
and 7). Preliminary results showed that increasing the spring constant decreases the cavity area in 
“active” treatments and further investigation is necessary to support this finding. This model 
provides the possibility of exploring targets for decreasing, and possibly eliminating the process 
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of progressive cavitation during the secondary injury in SCI. Once these targets are identified, 
treatments that attack these targets can be tested in vitro and in vivo to help speed up the pipeline 
from identifying targets to drug discovery and use in human subjects. With the increasing number 
of SCI patients and the detrimental effects SCI has on the daily lives of those living with the injury, 
finding effective treatments for all levels of injury is key. Much of today’s research and treatments 
focus on preventing further damage to the spinal cord and despite the multitude of drugs and targets 
that have been tested and continue to be tested, little to none have made it to circulation for SCI 
patients. These findings emphasize the benefits of in silico modeling to simulate real systems (such 
as astrocytes’ response to active macrophages) in a controlled setting. 
 
4.1 Limitations  
 
 With the use of computer modeling and simulation comes limitation,  most of which are 
unavoidable but can be improved based on new data from the system being modeled. Unlike Fitch 
et al.’s in vitro model which uses live cells with complex behaviors and compositions, the in silico 
model described here only has the input given to it. This means that my model exhibits behaviors 
based on the input data which can be lacking. However, if additional aspects such as new cells and 
interactions are added, they make for a less intuitive cellular response and a closer replication of 
the actions and interactions of live cells. Additionally, comparing the results of my model to that 
of the in vitro model is not a completely equivalent comparison because the in silico definition of 
levels of activation is based on density of macrophages used to create the conditioned media 
whereas the in silico levels of activation are based on speed of astrocytes. An assumption I make 
is that more activation is equivalent to higher speeds. The differences between my model’s “active” 
and “nonactive” treatments is the speed and because I do not have a way of increasing macrophage 
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density in the conditioned media in my in silico model  I assume that more activation corresponds 
to faster cells.  
 
4.2 Treatment of SCI progression 
 
 Understanding the gaps that exist in the field of SCI can be done by following the 
progression of treatment of SCI in a car accident victim. A car accident occurs and an individual 
sustains an injury to their spine. The spinal cord that lies inside the spine is compressed and cellular 
death occurs due to the mechanical injury (as explained in section 1.2 Spinal Cord Injury). The 
spine is then stabilized by first responders to limit further damage to the spinal cord. First 
responders focus on managing life threats through conducting a quick assessment of the patient’s 
airway, breathing, and circulation (Martin, Aleksanderek, and Fehlings 2015; Resnick 2013). 
During this time, though further mechanical injury is not likely to occur, the secondary (chemical) 
injury is beginning to affect the spinal cord.  
 When the patient arrives at the hospital, care is transferred to a trauma team which again 
obtains an overall impression of the patient while managing and presenting life threats. Once the 
trauma team has stabilized the patient, they are taken for imaging. Up until now, if a patient has 
sustained a SCI, their body continues experiencing the effects of the secondary injury. Though, 
the primary injury is not further affecting the patient at this stage, they are already sustaining more 
damage due to the secondary injury. Additionally, the most commonly used imaging technique, 
MRI, does not clearly identify what kind of damage is occurring in the spinal cord (Bozzo et al. 
2011). It cannot differentiate between cavitation, cell death, and inflammation among other 
processes, making it difficult to identify what exactly is happening in the spinal cord using an MRI. 
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 In SCI patients, time between injury and interventions is the difference between varying 
levels of recovery (Dvorak et al. 2015). Depending on the imaging results, the patient may or may 
not be taken to surgery. Typically if the patient does not need emergency surgery, they are 
monitored in an Intensive Care Unit (ICU). Sometimes, steroids, such as methylprednisolone 
(MSSP), which have anti-inflammatory effects, are administered to patients to reduce cell 
mortality (Bracken et al. 1997). However MSSP is typically only a feasible treatment option within 
eight hours of initial impact (Ahuja et al. 2016). Again, all throughout this time, the spinal cord is 
experiencing the detrimental effects of the secondary injury. This is a significant gap that exists in 
the treatment of SCI patients. 
 
4.3 Benefits of in silico models  
 
 Though many studies have been done on neuroprotective and regenerative drugs, none are 
currently prescribed to patients with SCI (Ahuja et al. 2016). Most of them have undergone or are 
in the process of undergoing clinical trials. After being released from the hospital, the patient will 
typically undergo months of physical therapy to help them regain some of their motor function but 
most patients never fully recover their typical motor and sensory functions. Further research into 
understanding how the body reacts to SCI and possible pathways that can be targeted to reduce the 
impact and magnitude of the secondary injury is key. Additionally, since there exists a multitude 
of studies and target pathways, a missing component is combination therapy (use of multiple 
therapies) to focus on both neuroprotection and regeneration post SCI.   
 In silico models, such as the one presented here, provide the possibility of streamlining the 
exploration process and simulating possible targets to provide a more guided exploration of 
treatments. This model can be improved to involve other complex aspects of the system (such as 
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adding macrophages in co-culture, or adding neurons and other glial cells) then used to test the 
effects of combining therapies and observing how they interact with one another. This also has 
implications beyond the spinal cord because the in silico model has proven to closely replicate the 
in vitro model, these methods of data gathering, model creation, and data input to create 
simulations can be applied to a wide range of other biological questions. Starting off with one 
accurate model of a biological system (such as the astrocytes in the spinal cord in this case) can 
lead to building upon that model and adding levels of complexity to then observe possible 
scenarios. My model supports the possibility of using in silico models to more easily run 
experiments based on data from the literature and to hypothesize how a model will react based on 
internal changes or changes within its environment. If in silico models are used more often to 
replicate biological systems, they can help us find new ways of treating patients living with a 
multitude of diseases and injuries.    
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
5 References 
 
Adamatzky AI. 1994. Identification Of Cellular Automata. London: Taylor & Francis Ltd. 
Ahuja CS, Cadotte DW, Fehlings M. 2018. Spinal Cord Injury. In: Principles of Neurological 
Surgery. 4th ed. Content Repository Only! p. 518–531.e3. 
Ahuja CS, Fehlings M. 2016. Bridging the Gap: Novel Neuroregenerative and Neuroprotective 
Strategies in Spinal Cord Injury. Stem Cells Transl Med. 5:914–924. doi:10.5966/sctm.2015-
0381. 
Ahuja CS, Martin AR, Fehlings MG. 2016. Recent advances in managing a spinal cord injury 
secondary to trauma. F1000Research. 5:1017. doi:10.12688/f1000research.7586.1. 
An G, Fitzpatrick BG, Christley S, Federico P, Kanarek A, Neilan RM, Oremland M, Salinas R, 
Laubenbacher R, Lenhart S. 2017. Optimization and Control of Agent-Based Models in Biology: 
A Perspective. Bull Math Biol. 79(1):63–87. doi:10.1007/s11538-016-0225-6. 
Arora S, Jain J, Rajwade JM, Paknikar KM. 2008. Cellular responses induced by silver 
nanoparticles: In vitro studies. Toxicol Lett. 179(2):93–100. 
doi:10.1016/J.TOXLET.2008.04.009. 
Banks J. 1998. Handbook of simulation : principles, methodology, advances, applications, and 
practice. Wiley. 
Bear MF, Connors BW, Paradiso MA, editors. 2007. Neurons and Glia. In: Neuroscience. 2nd 
ed. Lippincott Williams & Wilkins. p. 46–47. 
Beattie MS, Farooqui AA, Bresnahan JC. 2000. Review of Current Evidence for Apoptosis After 
Spinal Cord Injury. J Neurotrauma. 17(10):915–925. doi:10.1089/neu.2000.17.915. 
Birta LG, Arbez G. 2007. Modelling and Simulation Exploring Dynamic System Behaviour. 
Bonabeau E. 2002. Agent-based modeling: methods and techniques for simulating human 
systems. Proc Natl Acad Sci U S A. 99 Suppl 3(suppl 3):7280–7. doi:10.1073/pnas.082080899. 
Bortolussi L, Policriti A. 2008. Hybrid Systems and Biology . Continuous and Discrete 
Modeling for Systems Biology. 
Bozzo A, Marcoux J, Radhakrishna M, Pelletier J, Goulet B. 2011. The Role of Magnetic 
Resonance Imaging in the Management of Acute Spinal Cord Injury. J Neurotrauma. 
28(8):1401–1411. doi:10.1089/neu.2009.1236. 
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr 
DL, Hitchon PW, Marshall LF, et al. 1997. Administration of Methylprednisolone for 24 or 48 
Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury. JAMA. 
 42 
277(20):1597–1604. doi:10.1001/jama.1997.03540440031029. 
Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon 
SB. 2002. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 
416(6881):636–640. doi:10.1038/416636a. 
Brodland GW. 2015. How computational models can help unlock biological systems. Semin Cell 
Dev Biol. 47–48:62–73. doi:10.1016/J.SEMCDB.2015.07.001. 
Byrnes KR, Stoica BA, Fricke S, Di Giovanni S, Faden AI. 2007. Cell cycle activation 
contributes to post-mitotic cell death and secondary damage after spinal cord injury. Brain. 
130(11):2977–2992. doi:10.1093/brain/awm179. 
Casha S, Zygun D, McGowan MD, Bains I, Yong VW, John Hurlbert R. 2012. Results of a 
phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain. 
135(4):1224–1236. doi:10.1093/brain/aws072. 
Cregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J. 2014. Functional regeneration 
beyond the glial scar. Exp Neurol. 253:197–207. doi:10.1016/j.expneurol.2013.12.024. 
Dvorak MF, Noonan VK, Fallah N, Fisher CG, Finkelstein J, Kwon BK, Rivers CS, Ahn H, rô 
me Paquet J, Tsai EC, et al. 2015. The Influence of Time from Injury to Surgery on Motor 
Recovery and Length of Hospital Stay in Acute Traumatic Spinal Cord Injury: An Observational 
Canadian Cohort Study. J Neurotrauma. 32:645–654. doi:10.1089/neu.2014.3632. 
Emmett CJ, Lawrence JM, Raisman G, Seeley PJ. 1991. Cultured epithelioid astrocytes migrate 
after transplantation into the adult rat brain. J Comp Neurol. 311(3):330–341. 
doi:10.1002/cne.903110304. 
Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew M V. 2004. Reactive 
Astrocytes Protect Tissue and Preserve Function after Spinal Cord Injury. J Neurosci. 
24(9):2143–2155. doi:10.1523/JNEUROSCI.3547-03.2004. 
Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. 2006. Minocycline 
neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal 
cord injury. J Neurochem. 97(5):1314–1326. doi:10.1111/j.1471-4159.2006.03799.x. 
Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. 1999. Cellular and Molecular 
Mechanisms of Glial Scarring and Progressive Cavitation: In Vivo and In Vitro Analysis of 
Inflammation-Induced Secondary Injury after CNS Trauma. J Neurosci. 19(19):8182–8198. 
doi:10.1523/jneurosci.19-19-08182.1999. 
Fujiki M, Furukawa Y, Kobayashi H, Abe T, Ishii K, Uchida S, Kamida T. 2005. 
Geranylgeranylacetone limits secondary injury, neuronal death, and progressive necrosis and 
cavitation after spinal cord injury. Brain Res. 1053(1–2):175–184. 
doi:10.1016/J.BRAINRES.2005.06.055. 
 43 
Fujiki M, Kobayashi H, Isono M. 2003. High frequency electrical stimulation attenuates 
progressive necrosis and cavitation following spinal cord injury. In: Brain Edema XII. Vienna: 
Springer Vienna. p. 395–397. 
Garrido-Mesa N, Zarzuelo A, Gálvez J. 2013. Minocycline: far beyond an antibiotic. Br J 
Pharmacol. 169(2):337–52. doi:10.1111/bph.12139. 
Germain RN, Meier-Schellersheim M, Nita-Lazar A, Fraser IDC. 2011. Systems Biology in 
Immunology: A Computational Modeling Perspective. Annu Rev Immunol. 29(1):527–585. 
doi:10.1146/annurev-immunol-030409-101317. 
Di Giovanni S, Knoblach SM, Brandoli C, Aden SA, Hoffman EP, Faden AI. 2003. Gene 
profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol. 53(4):454–
468. doi:10.1002/ana.10472. 
Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B, Faden AI. 2005. Cell 
cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after 
traumatic brain injury. Proc Natl Acad Sci U S A. 102(23):8333–8. 
doi:10.1073/pnas.0500989102. 
Goff DA, Bauer KA, Mangino JE. 2014. Bad Bugs Need Old Drugs: A Stewardship Program’s 
Evaluation of Minocycline for Multidrug-Resistant Acinetobacter baumannii Infections. Clin 
Infect Dis. 59(suppl_6):S381–S387. doi:10.1093/cid/ciu593. 
Guertin PA. 2012. Central pattern generator for locomotion: anatomical, physiological, and 
pathophysiological considerations. Front Neurol. 3:183. doi:10.3389/fneur.2012.00183. 
Hypothermia after Cardiac Arrest Study Group. 2002. Mild Therapeutic Hypothermia to 
Improve the Neurologic Outcome after Cardiac Arrest. N Engl J Med. 346(8):549–556. 
doi:10.1056/NEJMoa012689. 
Kamiya K, Koda M, Furuya T, Kato K, Takahashi H, Sakuma T, Inada T, Ota M, Maki S, 
Okawa A, et al. 2015. Neuroprotective therapy with granulocyte colony-stimulating factor in 
acute spinal cord injury: a comparison with high-dose methylprednisolone as a historical control. 
Eur Spine J. 24(5):963–967. doi:10.1007/s00586-014-3373-0. 
Kawabe J, Koda M, Hashimoto M, Fujiyoshi T, Furuya T, Endo T, Okawa A, Yamazaki M. 
2011. Neuroprotective effects of granulocyte colony-stimulating factor and relationship to 
promotion of angiogenesis after spinal cord injury in rats. J Neurosurg Spine. 15(4):414–421. 
doi:10.3171/2011.5.SPINE10421. 
Környei, Z, Czirók A, Vicsek T, Madarász E. 2000. Proliferative and Migratory Responses of 
Astrocytes to In Vitro Injury. 
Krogh A, Hael Brown C, Saira Mian I, Sjj Olander Y , D A Vid Haussler K. 1993. Hidden 
Markov Models in Computational Biology: Applications to Protein Modeling UCSC-CRL-93-
 44 
32. 
Kuiper JWP, van Horssen R, Oerlemans F, Peters W, van Dommelen MMT, te Lindert MM, ten 
Hagen TLM, Janssen E, Fransen JAM, Wieringa B. 2009. Local ATP Generation by Brain-Type 
Creatine Kinase (CK-B) Facilitates Cell Motility. Aziz SA, editor. PLoS One. 4(3):e5030. 
doi:10.1371/journal.pone.0005030. 
Kwon BK, Mann C, Sohn HM, Hilibrand AS, Phillips FM, Wang JC, Fehlings MG. 2008. 
Hypothermia for spinal cord injury. Spine J. 8(6):859–874. doi:10.1016/j.spinee.2007.12.006. 
Leal-Filho MB. 2011. Spinal cord injury: From inflammation to glial scar. Surg Neurol Int. 
2:112. doi:10.4103/2152-7806.83732. 
Levi AD, Green BA, Wang MY, Dietrich WD, Brindle T, Vanni S, Casella G, Elhammady G, 
Jagid J. 2009. Clinical Application of Modest Hypothermia after Spinal Cord Injury. J 
Neurotrauma. 26(3):407–415. doi:10.1089/neu.2008.0745. 
Lo TP, Cho K-S, Garg M Sen, Lynch MP, Marcillo AE, Koivisto DL, Stagg M, Abril RM, Patel 
S, Dietrich WD, et al. 2009. Systemic hypothermia improves histological and functional outcome 
after cervical spinal cord contusion in rats. J Comp Neurol. 514(5):433–448. 
doi:10.1002/cne.22014. 
Maikos JT, Qian Z, Metaxas D, Shreiber DI. 2008. Finite Element Analysis of Spinal Cord 
Injury in the Rat. J Neurotrauma. 25(7):795–816. doi:10.1089/neu.2007.0423. 
Martin AR, Aleksanderek I, Fehlings MG. 2015. Diagnosis and Acute Management of Spinal 
Cord Injury: Current Best Practices and Emerging Therapies. Curr Trauma Reports. 1(3):169–
181. doi:10.1007/s40719-015-0020-0. 
Martin R, Raffo D. 2000. A Model of the Software Development Process Using Both 
Continuous and Discrete Models. Softw Process Improv Pract. 5(2–3):147–157. 
Mayo Clinic Staff. 2017. Spinal cord injury - Symptoms and causes - Mayo Clinic. Mayo Clin. 
[accessed 2018 Dec 9]. https://www.mayoclinic.org/diseases-conditions/spinal-cord-
injury/symptoms-causes/syc-20377890. 
McDonald JW, Becker D, Huettner J. 2004. Spinal Cord Injury. In: Handbook of Stem Cells. 
Academic Press. p. 701–712. 
Mothe AJ, Tator CH. 2012. Advances in stem cell therapy for spinal cord injury. J Clin Invest. 
122(11):3824–34. doi:10.1172/JCI64124. 
National SCI Statistical Center. 2019. Spinal Cord Injury Facts and Figures at a Glance. 
Norton K-A, Wininger M, Bhanot G, Ganesan S, Barnard N, Shinbrot T. 2010. A 2D 
mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression. J 
 45 
Theor Biol. 263(4):393–406. doi:10.1016/j.jtbi.2009.11.024. 
Orphan Drug Status for Alvocidib. 2014 May 25. Oncol Times. 36(10):91. 
doi:10.1097/01.COT.0000450374.31680.1d. 
Resnick DK. 2013. Updated Guidelines for the Management of Acute Cervical Spine and Spinal 
Cord Injury. Neurosurgery. 72:1. doi:10.1227/NEU.0b013e318276ee7e. 
Shannon RE. 1998. INTRODUCTION TO THE ART AND SCIENCE OF SIMULATION. In: 
1998 Winter Simulation Conference. 
Shiffman D. 2012. Nature of Code. Fry S, editor. California. 
Silver JR. 2005. History of the treatment of spinal injuries. Postgr Med J. 81(952):108–114. 
doi:10.1136/pgmj.2004.019992. 
Sofroniew M V. 2009. Molecular dissection of reactive astrogliosis and glial scar formation. 
Trends Neurosci. 32(12):638–647. doi:10.1016/J.TINS.2009.08.002. 
Solovyev A, Mi Q, Tzen Y-T, Brienza D, Vodovotz Y. 2013. Hybrid Equation/Agent-Based 
Model of Ischemia-Induced Hyperemia and Pressure Ulcer Formation Predicts Greater 
Propensity to Ulcerate in Subjects with Spinal Cord Injury. Peirce SM, editor. PLoS Comput 
Biol. 9(5):e1003070. doi:10.1371/journal.pcbi.1003070. 
Squire L, Berg D, Bloom F, Lac S Du, Ghosh A, Spitzer N. 2008. Fundamental neuroscience, 
third edition. 3rd ed. London: Academic Press publications. 
Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith 
LL, Zhao Y, Ling Y, et al. 2013. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a 
novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic 
leukemia. Leuk Res. 37(10):1195–1199. doi:10.1016/J.LEUKRES.2013.06.006. 
Tan AR, Swain SM. 2002. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast 
cancer therapy. Semin Oncol. 29(3 Suppl 11):77–85. 
Tator CH, Fehlings MG. 1991. Review of the secondary injury theory of acute spinal cord 
trauma with emphasis on vascular mechanisms. J Neurosurg. 75(1):15–26. 
doi:10.3171/jns.1991.75.1.0015. 
Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, Langer R, Snyder EY. 2002. 
Functional recovery following traumatic spinal cord injury mediated by a unique polymer 
scaffold seeded with neural stem cells. PNAS. 99(5):3024–3029. doi:10.1073/pnas.082526499. 
Wang X, Budel S, Baughman K, Gould G, Song K-H, Strittmatter SM. 2009. Ibuprofen 
Enhances Recovery from Spinal Cord Injury by Limiting Tissue Loss and Stimulating Axonal 
Growth. J Neurotrauma. 26(1):81–95. doi:10.1089/neu.2007.0464. 
 46 
Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW. 2003. Neuroprotection by minocycline 
facilitates significant recovery from spinal cord injury in mice. Brain. 126(7):1628–1637. 
doi:10.1093/brain/awg178. 
Wolfram S. 1984. Cellular Automata as Models of Complexity. Nat Int Wkly J Sci. 311:419–
424. 
World Health Organization (WHO). 2013. Spinal cord injury. [accessed 2019 Apr 16]. 
https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury. 
Yuk JCC. 2016. Spinal Cord Modelling for Understanding and Preventing Injury. University of 
Western Australia Supervisor: 
Zafarparandeh I, Erbulut DU, Lazoglu I, Ozer AF. 2014. Development of a finite element model 
of the human cervical spine. Turk Neurosurg. 24(3):312–318. doi:10.5137/1019-5149.JTN.8486-
13.0. 
Zheng B, Lorenzana AO, Ma L. 2019 Apr. Understanding the axonal response to injury by in 
vivo imaging in the mouse spinal cord: A tale of two branches. Exp Neurol. 
doi:10.1016/j.expneurol.2019.04.008. 
Zhou HF, Lee LH-C, Lund RD. 1990. Timing and patterns of astrocyte migration from 
xenogeneic transplants of the cortex and corpus callosum. J Comp Neurol. 292(2):320–330. 
doi:10.1002/cne.902920213. 
Zhou X, Kuhl ME. 2011. A sustainability toolkit for simulaiton: Recent developments and future 
capabilities. In: Proceedings of the 2011 Winter Simulation Conference. p. 850–858. 
Zimmer MB, Nantwi K, Goshgarian HG. 2007. Effect of spinal cord injury on the respiratory 
system: basic research and current clinical treatment options. J Spinal Cord Med. 30(4):319–330. 
Ziraldo C, Solovyev A, Allegretti A, Krishnan S, Henzel MK, Sowa GA, Brienza D, An G, Mi 
Q, Vodovotz Y. 2015. A Computational, Tissue-Realistic Model of Pressure Ulcer Formation in 
Individuals with Spinal Cord Injury. Mac Gabhann F, editor. PLOS Comput Biol. 
11(6):e1004309. doi:10.1371/journal.pcbi.1004309. 
 
 
 
 
 
 
 
 
 
 47 
6 Appendix 
 
6.1 Supplemental Figures 
 
 
 
Figure S1: In vitro vs. in silico cavity area comparison. The in silico model (in blue) closely 
matches the in vitro model (in black) described by Fitch et al., providing a measure of success. 
 
 
6.2 Processing Code 
 
Cell class: 
1. /* Cell is the parent class for all types of cells: neurons, astrocytes, and immune cel
ls*/   
2. class Cell {   
3.   float size;   
4.   PVector location;   
5.   PVector velocity;   
6.   PVector acceleration;   
7.    
8.   Cell() {   
9.     size = random(10, 30);   
10.     location = new PVector(random(500), random(500));   
11.     velocity = new PVector(0, 0);   
12.     acceleration = new PVector(0, 0);   
13.   }   
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14.    
15.   //displays the cell as an elllipse if it is alive   
16.   void display() {   
17.     fill(1);   
18.     ellipse(location.x, location.y, size, size);   
19.   }   
20.    
21.   //updates the location of the cell based on velocity   
22.   void update() {   
23.     velocity.add(acceleration);   
24.     location.add(velocity);   
25.     acceleration.mult(0); //set acceleration to zero so it does not continue speeding u
p   
26.   }   
27.    
28.   //applies a force to change the acceleration   
29.   void applyForce(PVector force) {   
30.     acceleration.add(force);   
31.   }   
32. }   
 
 
Astrocyte class: 
1. //Astrocytes. The cell body of an astrocyte spans 10-20 microns and   
2. //its processes radiate out for another 20-30 microns, forming the    
3. //stellate glial cell.   
4.    
5. class Astrocyte extends Cell {   
6.   float stepSize;   
7.    
8.   Astrocyte() {   
9.     size = 20;    
10.     location = new PVector(random(500), random(500));   
11.     velocity = new PVector(0, 0);   
12.     acceleration = new PVector(0, 0);   
13.     //stepSize = 0.2;   
14.     stepSize = 0.0084;   
15.   }   
16.    
17.   void display() {   
18.     fill(51, 204, 204);   
19.     stroke(1);   
20.     ellipse(location.x, location.y, size, size);   
21.   }   
22.    
23.    
24.   //From my lab 2 programming nature course   
25.   void randStep() {   
26.     int xRand = int(random(3))-1; // -1, 0 , or 1   
27.     int yRand = int (random(3)) -1 ; // -1, 0 , or 1   
28.    
29.     location.x += stepSize * xRand;   
30.     location.y += stepSize * yRand;   
31.   }   
32.    
33.   void checkEdges() {   
34.     location.x = constrain(location.x, size/2, width - size/2);   
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35.     location.y = constrain(location.y, size/2, height - size/2);   
36.   }   
37.    
38.   //based off Nature of Code chapter 3.10   
39.   //Spring forces   
40.   PVector bounce(Astrocyte other, float springForce) {   
41.     float k = springForce;   
42.     PVector dist = PVector.sub(other.location, location);//how far away the cells curre
ntly are   
43.     float distWant = other.size/2 + size/2; //dist should be at least sum of radii ("re
st length" in spring forces)   
44.     float curLen = dist.mag();   
45.    
46.     float x = distWant - curLen;   
47.     dist.normalize();   
48.    
49.     PVector force = dist.mult(-1*k*x);   
50.     return force; //return the force PVector so we can add them all   
51.   }   
52. }   
 
 
Main Sketch: 
1. /*   
2.  migration of astrocytes in the precense of activated macrophages  
3.  random movement that results in "pockets"  
4.  cells are "plated" in confluency ==> 80% of the plate is covered  
5. */   
6.    
7. //if size = 20-30, area = 400 -900 so 200,000/400 = 500   
8. Astrocyte[] astrocytes = new Astrocyte[500];    
9.    
10. int state; //if cells are beng plated =0, if cells are moving =1   
11. int cellSize = 20;    
12. int iter; //number of draw iterations so far   
13. int simNum; //simulation number   
14. boolean active;   
15. int hour;    
16. float activeStep; //how much cells moves in randStep if macrophages are activated   
17. float springConstant; //the spring constant for the cells   
18.    
19. int trialNum; //helps keep images folder and textfile connected   
20. //ANALYSIS STUFF   
21. PrintWriter output; //output file   
22. int whitePixels; //number of white pixels in the image   
23.    
24. String fileType; //activated or non activated...   
25. String fileName;   
26.    
27. void setup() {   
28.   background(255);   
29.   size(500, 500);   // in microns!!   
30.   state = 0;   
31.   simNum = 1;   
32.   active = false;    
33.   activeStep = 0.25;   
34.   springConstant = 0.0001;   
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35.   trialNum = 14;   
36.   fileType = "both_trials" + trialNum;   
37.   fileName = "NonActivated";   
38.   output = createWriter("data_" +fileType+ ".txt");   
39.   output.println("FileName" + "\t" + "WhitePixels" + "\t" + "TotalPixels" + "\t" + "spr
ing force: "+ springConstant);   
40. }   
41.    
42. void draw() {   
43.   /* RUN SIMULATION FOR ASTROCYTES */   
44.   while (simNum <=30) { //go through 30 simulations   
45.     if (state == 0) {   
46.       iter = 0; //set to zero at the atrt of each new simulation   
47.       for (int i =0; i< astrocytes.length; i++) {   
48.         astrocytes[i] = new Astrocyte();   
49.         int randX = 2*int(random(3))-1; // -1, 0 , or 1   
50.         int randY = 2*int (random(3)) -1 ; // -1, 0 , or 1   
51.    
52.         astrocytes[i].location.x = (((i * cellSize)+ cellSize/2) % width) + randX;   
53.         astrocytes[i].location.y = (int(i/(width/cellSize)) * cellSize + cellSize/2) + 
randY + 50;   
54.         astrocytes[i].display();   
55.       }   
56.       state = 1;   
57.     } else {     
58.       background(255);   
59.       bounceCells(astrocytes);   
60.       if (iter>=2400) { //48 hours --> start treatment   
61.         if (active) { //if in active state, change stepSize   
62.           for (int i =0; i< astrocytes.length; i++) {   
63.             astrocytes[i].stepSize = activeStep;   
64.           }   
65.         }   
66.         if (iter%300 == 0) {   
67.           hour = ((iter/300) * 6) - 48;   
68.           save("images_trial" +trialNum+ "/" +simNum+ "_" +fileName+ "_Astrocytes_" +ho
ur+ "hrs.jpeg");   
69.           if (hour == 0) {   
70.             analyzeImage();    //ANALYSIS   
71.             output.println(fileName +"_hr_" + hour + "\t" + whitePixels + "\t" + pixels
.length);   
72.           }   
73.         }   
74.       }   
75.       /*1200 = 24 hrs; 3600 = 72 hrs  
76.        move 0.2 microns per iteration  
77.        want to move 10 microns per hour  
78.        (10 microns / hour) * (1 iter / 0.2 microns) = 50 iter /hour  
79.        500 iter -> 1 hr;  300 iter -> 6 hrs  
80.        */   
81.       if (iter >= 3600) { // 72 hours --> end treatment   
82.         //noLoop();   
83.         analyzeImage();     //ANALYSIS   
84.         output.println(fileName +"_hr_" + hour + "\t" + whitePixels + "\t" + pixels.len
gth);   
85.    
86.         if (active) {//since we start with nonactivated, means one Simulation is done   
87.           active = false;   
88.           fileName = "NonActivated";   
89.           state = 0; //start at plating again   
90.           simNum++; //next simulation   
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91.           // output.close();   
92.           //noLoop();   
93.         } else if (!active) {   
94.           active = true;   
95.           state = 0; //simulaition for new type, start at plating again   
96.           fileName = "Activated";   
97.           //loop();   
98.         }   
99.       }   
100.       iter ++;   
101.     }   
102.   } //end of while loop   
103.   output.close();   
104. }   
105.    
106. void analyzeImage() {   
107.   loadPixels();   
108.   whitePixels = 0;   
109.   for (int x = 0; x<width; x++) { //loop through evern column of pixels   
110.     for (int y = 50; y<450; y++) { //loop through every row of pixels from 50 to
 450   
111.       int pixelLoc = x + y * width;   
112.       if (pixels[pixelLoc] >= color(150)) {   
113.         whitePixels ++;   
114.         pixels[pixelLoc] = color(200, 100, 200);   
115.       }// else {   
116.       //  pixels[pixelLoc] = color(98, 240, 255);   
117.     }   
118.   }   
119.   //}   
120.   updatePixels();   
121. }   
122. void bounceCells(Astrocyte[] astrocytes) {   
123.   for (int i =0; i < astrocytes.length; i++) {   
124.     astrocytes[i].randStep();   
125.     for (int j = i+1; j < astrocytes.length; j++) {    
126.       float r1 = astrocytes[i].size/2;   
127.       float r2 = astrocytes[j].size/2;   
128.       float dist = astrocytes[i].location.dist(astrocytes[j].location);   
129.       float distWant = r1 + r2;   
130.       if (dist < distWant) {   
131.         PVector force = astrocytes[i].bounce(astrocytes[j], springConstant);   
132.         astrocytes[i].applyForce(force);   
133.         //if one cell got positive force, the other needs to get the negative fo
rce...   
134.         //will not get added in twice since j is i+1 so we never go to cells alr
eady checked   
135.         astrocytes[j].applyForce(force.mult(-1));   
136.       }   
137.     }   
138.   }   
139.   for (int i =0; i< astrocytes.length; i++) {   
140.     float c = 0.1; //friction from nature of code 2.7   
141.     PVector friction = astrocytes[i].velocity.copy();   
142.     friction.mult(-1);   
143.     friction.normalize();   
144.     friction.mult(c);   
145.     astrocytes[i].applyForce(friction);   
146.     astrocytes[i].update(); //adds acceleration to velocity and vel to location 
then sets acc to 0   
147.     astrocytes[i].checkEdges();   
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148.     astrocytes[i].display();   
149.   }   
150. }   
 
 
 
 
 
6.3 R Code 
 
knitr::opts_chunk$set(echo = TRUE) 
library(ggplot2) 
library(gridExtra) #used to create a table 
#t-test data 
all_change <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_for_sta
ts/all_change.csv") 
#data for testing assumptions 
all_change_anova <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_f
or_stats/all_change_anova.csv") 
#data for combined plot 
plot_data <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_for_stat
s/plot_data.csv") 
#data for seperate plots 
plot_data_sep <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_for_
stats/plot_data_separate.csv") 
#z-test data 
ratio_area <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_for_sta
ts/ratio_area_critical_vals.csv") 
#data for t-test on start point for active and nonactive treatments 
all_start <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_for_stat
s/all_start.csv") 
#testing assumptions of start data --> NOT NECESSARY THOUGH!!!  
all_start_anova <- read.csv(file="~/Desktop/SPROJ/Take2/Analysis/Excel_csv_fo
r_stats/all_start_anova.csv") 
 
#t-tests hypotheses 1 
t.test(all_start$start_nonactive_0.25, all_start$start_active_0.25, var.equal 
= TRUE) 
t.test(all_start$start_nonactive_0.3, all_start$start_active_0.3, var.equal = 
TRUE) 
t.test(all_start$start_nonactive_1.4, all_start$start_active_1.4, var.equal = 
TRUE) 
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#t-tests hypotheses 2 
t.test(all_change$change_nonactive_0.25, all_change$change_active_0.25, var.e
qual = TRUE) 
model_0.25 <- lm(all_change_anova$whitePixels_0.25 ~ all_change_anova$type_0.
25) 
anova(model_0.25) 
 
t.test(all_change$change_nonactive_0.3, all_change$change_active_0.3, var.equ
al = TRUE) 
model_0.3 <- lm(all_change_anova$whitePixels_0.3 ~ all_change_anova$type_0.3) 
anova(model_0.3) 
 
t.test(all_change$change_nonactive_1.4, all_change$change_active_1.4, var.equ
al = TRUE) 
model_1.4 <- lm(all_change_anova$whitePixels_1.4 ~ all_change_anova$type_1.4) 
anova(model_1.4) 
 
#z-tests hypotheses 3 
#this z.test function is a combination from Gabriel Perron's Code and code fr
om the statistical analysis with r for dummies book: https://www.dummies.com/
education/math/statistics/z-testing-r/ 
 
#z.test = function(a, mu, SD) { #create function and define inputs to provide 
 # z.statistic = (mean(a) - mu) / SD #compute the function using inputs provi
ded 
  #return(z.statistic) #print value computed above 
#} 
 
z.test = function(a, mu, SD) { #create function and define inputs to provide 
  one.tail.prob <- NULL #probability that the z_score is greater than x 
  two.tail.prob <- NULL #probability that the z_score is greater than x and l
ess than (-) x 
   
  z.stat <- (mean(a) - mu) / SD #compute z_score/z_test using inputs provided 
  one.tail.prob <- pnorm(abs(z.stat),lower.tail = FALSE) 
  two.tail.prob <- 2 * one.tail.prob 
   
  cat(" z =", z.stat, "\n", "two-tailed probability =", two.tail.prob, "\n") 
#"one-tailed probability =", one.tail.prob,"\n",  
 # cat("two-tailed probability =", two.tail.prob, "\n") #"one-tailed probabil
ity =", one.tail.prob,"\n",  
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  #return(z.stat) #print z_stat computed above 
} 
 
z.test(ratio_area$area_0.25, 1.6, 0.2)  #activated - 5 --> area 1.6  speed 0.
25 
z.test(ratio_area$area_0.3, 1.8, 0.15)  #activated - 10 --> area 1.8  speed 0
.3 
z.test(ratio_area$area_1.4, 2.4, 0.3)  #activated - 12 --> area 2.4  speed 1.
4 
# In Vitro 
tickMarks3 <- c("Control", "Activated - 5",  "Activated -10","Activated - 12"
) 
 
ggplot(plot_data_sep, aes(x = Condition_inVitro, y=Area_inVitro)) + 
  geom_bar(stat = "identity", fill = "black") +  
  xlab("") +  
 ylab("Astrocyte Cavity Area") +  
  scale_x_discrete(labels = tickMarks3, limits = plot_data_sep$Condition_inVi
tro)+ 
  scale_y_continuous(expand = c(0,0), breaks=seq(0,3.5,0.2), limits = c(0,3)) 
+  #y from 0 - 3 increasing by 0.2 
  scale_colour_manual(values=c("black")) + #CHANGE COLORS (USE RGB COLOR PICK
ER) 
  geom_errorbar(aes(ymin=Area_inVitro-StandardError_inVitro, ymax=Area_inVitr
o+StandardError_inVitro), width=.2,position=position_dodge(.9)) + 
  annotate("text", x = c("Activated - 5","Activated - 10", "Activated - 12"), 
y = c(2,2.2,2.8), label = c("*","*","**")) + 
 # annotate("text", x = c("Control", "Activated - 5","Activated - 10", "Activ
ated - 12"), y = c(2.8, 2,2.2,2.8), label = c("A", "*","*","**")) + 
 # coord_cartesian(ylim = (0, 3))+ 
  theme_classic() 
 
#In Silico 
tickMarks2 <- c(expression("Control 0.084"*mu*"m"), 
                expression("Activated 0.25"*mu*"m"),  
                expression("Activated 0.3"*mu*"m"),   
                expression("Activated 1.4"*mu*"m")) 
 
ggplot(plot_data_sep, aes(x = Condition_inSilico, y=Area_inSilico)) + 
  geom_bar(stat = "identity", fill = "#56B4E9") +  
  xlab("") +  
  ylab("Astrocyte Cavity Area") +  
  annotate("text",x= c("Activated 0.25", "Activated 0.3", "Activated 1.4"), y 
= c(2, 2.2, 2.6), label = c("***","***","***")) + 
  #annotate("text",x= c("Control 0.084","Activated 0.25", "Activated 0.3", "A
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ctivated 1.4"), y = c(2.7, 2, 2.2, 2.6), label = c("B","***","***","***")) + 
  scale_x_discrete(labels = tickMarks2, limits = plot_data_sep$Condition_inSi
lico) + 
  scale_y_continuous(expand = c(0,0), breaks=seq(0,2.7,0.2), limits = c(0,2.8
)) +  #y from 0 - 3 increasing by 0.2 
  geom_errorbar(aes(ymin=Area_inSilico-StandardError_inSilico, ymax=Area_inSi
lico+StandardError_inSilico), width=.2,position=position_dodge(.9)) + 
  theme_classic() 
#COMBINED 
tickMarks <- c("Control",expression("Control 0.084"*mu*"m"), "Activated - 5", 
expression("Activated 0.25"*mu*"m"), "Activated -10",expression("Activated 0.
3"*mu*"m"), "Activated - 12", expression("Activated 1.4"*mu*"m")) 
 
#legend inside - BEST ONE 
ggplot(plot_data, aes(x = Condition, y=Area, fill=Type)) + 
  geom_bar(stat = "identity") +  
  xlab("") +  
  ylab("Astrocyte Cavity Area") +  
  scale_x_discrete(labels = tickMarks, limits = plot_data$Condition)+ 
  scale_y_continuous(expand = c(0,0), breaks=seq(0,3,0.2))+ 
  scale_fill_manual(values=c("#56B4E9", "black"))+ #CHANGE COLORS (USE RGB CO
LOR PICKER) 
  geom_errorbar(aes(ymin=Area-StandardError, ymax=Area+StandardError), width=
.2,position=position_dodge(.9))+ 
  theme_classic()+ 
  theme(legend.position = c(0.3, 0.9), legend.direction = "horizontal", legen
d.text=element_text(face = "italic"), axis.text.x = element_text(angle=90))+ 
  labs(fill = "Model") #change legend title 
 
 
#TESTING ASSUMPTIONS (repeated for all three speeds) 
#get unstandardized predicted and residual values 
unstandardizedPredicted <- predict(model_0.25) 
unstandardizedResiduals <- resid(model_0.25) 
 
#get standardized values 
#This will allow you to look at the residuals for any analysis oncommon axis 
with a mean of zero. 
standardizedPredicted  <- (unstandardizedPredicted - mean(unstandardizedPredi
cted)) / sd(unstandardizedPredicted) 
standardizedResiduals <- (unstandardizedResiduals - mean(unstandardizedResidu
als)) / sd(unstandardizedResiduals) 
 
#create residuals histogram 
hist(standardizedResiduals, freq = FALSE) 
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#add normal curve 
curve(dnorm, add = TRUE) 
par(mfrow=c(1,1)) 
plot(model_0.25) 
 
 
 
 
